| Encompass Health Home Health Of Central Oklahoma | |
| 209 Nw 48th Ave, Norman, Oklahoma 73072 | |
| (405) 360-0041 | |
| Name | Encompass Health Home Health Of Central Oklahoma |
|---|---|
| Location | 209 Nw 48th Ave, Norman, Oklahoma |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 377196 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 73002, 73003, 73007, 73008, 73010, 73012, 73013, 73020, 73025, 73026, 73030, 73031, 73034, 73044, 73045, 73049, 73051, 73052, 73054, 73057, 73068, 73069, 73070, 73071, 73072, 73074, 73075, 73078, 73080, 73084, 73086, 73089, 73093, 73095, 73098, 73099, 73103, 73104, 73105, 73106, 73107, 73108, 73109, 73110, 73111, 73112, 73114, 73115, 73116, 73117, 73118, 73119, 73120, 73121, 73122, 73124, 73125, 73127, 73128, 73129, 73130, 73131, 73132, 73134, 73135, 73139, 73141, 73142, 73143, 73149, 73150, 73151, 73153, 73159, 73160, 73162, 73163, 73165, 73170, 73172, 73173, 73179, 73401, 73430, 73433, 73434, 73437, 73438, 73442, 73443, 73446, 73447, 73448, 73453, 73456, 73458, 73459, 73460, 73463, 73481, 73505, 73520, 73565, 73569, 73573, 74531, 74534, 74538, 74570, 74572, 74801, 74802, 74804, 74818, 74820, 74821, 74825, 74826, 74827, 74830, 74831, 74836, 74840, 74843, 74844, 74848, 74849, 74851, 74852, 74854, 74856, 74857, 74864, 74865, 74867, 74868, 74869, 74871, 74872, 74873, 74878, 74884, 76119 |
| NPI Number | 1689654949 |
| Organization Name | HEALTHCARE INNOVATIONS-TRAVERTINE HEALTH SERVICES, LLC |
| Doing Business As | ENHABIT HOME HEALTH OF CENTRAL OKLAHOMA |
| Address | 209 Nw 48th Ave, Norman, OK 73072 |
| Phone Number | 405-360-0041 |
News Archive
Schizophrenia has long been known to be highly heritable and is present in approximately 1% of the population. Researchers have been following two paths in their pursuit of identifying schizophrenia risk genes.
Scientists have developed a simple, cheap, accurate test to find undetected landmines.
Researchers at the University of Pittsburgh Cancer Institute (UPCI) and the School of Medicine have discovered that inhibiting a key molecule in a DNA repair pathway could provide the means to make cancer cells more sensitive to radiation therapy while protecting healthy cells.
In this survey, conducted by the Commonwealth Fund and Modern Healthcare, 89 percent of respondents supported moving forward with the measure's implementation. In related news, the National Committee for Quality Assurance plans this month to begin accrediting accountable care organizations. Meanwhile, in local coverage, North Carolina's health exchange grant remains unspent and a rural California county has its own health reform calculus.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.
› Verified 4 days ago
| Quality Rating: |
News Archive
Schizophrenia has long been known to be highly heritable and is present in approximately 1% of the population. Researchers have been following two paths in their pursuit of identifying schizophrenia risk genes.
Scientists have developed a simple, cheap, accurate test to find undetected landmines.
Researchers at the University of Pittsburgh Cancer Institute (UPCI) and the School of Medicine have discovered that inhibiting a key molecule in a DNA repair pathway could provide the means to make cancer cells more sensitive to radiation therapy while protecting healthy cells.
In this survey, conducted by the Commonwealth Fund and Modern Healthcare, 89 percent of respondents supported moving forward with the measure's implementation. In related news, the National Committee for Quality Assurance plans this month to begin accrediting accountable care organizations. Meanwhile, in local coverage, North Carolina's health exchange grant remains unspent and a rural California county has its own health reform calculus.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.
› Verified 4 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 98.3 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 99.2 | 98.6 |
| How often the home health team checked patients’ risk of falling | 99.9 | 99.6 |
| How often the home health team checked patients for depression | 99.6 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 83 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 86.1 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 99.4 | 96.4 |
News Archive
Schizophrenia has long been known to be highly heritable and is present in approximately 1% of the population. Researchers have been following two paths in their pursuit of identifying schizophrenia risk genes.
Scientists have developed a simple, cheap, accurate test to find undetected landmines.
Researchers at the University of Pittsburgh Cancer Institute (UPCI) and the School of Medicine have discovered that inhibiting a key molecule in a DNA repair pathway could provide the means to make cancer cells more sensitive to radiation therapy while protecting healthy cells.
In this survey, conducted by the Commonwealth Fund and Modern Healthcare, 89 percent of respondents supported moving forward with the measure's implementation. In related news, the National Committee for Quality Assurance plans this month to begin accrediting accountable care organizations. Meanwhile, in local coverage, North Carolina's health exchange grant remains unspent and a rural California county has its own health reform calculus.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.
› Verified 4 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 83.7 | 79.6 |
| How often patients got better at getting in and out of bed | 79.7 | 81.1 |
| How often patients got better at bathing | 86.6 | 82.3 |
| How often patients’ breathing improved | 79.8 | 82.8 |
| How often patients’ wounds improved or healed after an operation | 96.9 | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 85 | 75 |
| How often home health patients had to be admitted to the hospital | 16.4 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 17.1 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 93.4 | 94 |
News Archive
Schizophrenia has long been known to be highly heritable and is present in approximately 1% of the population. Researchers have been following two paths in their pursuit of identifying schizophrenia risk genes.
Scientists have developed a simple, cheap, accurate test to find undetected landmines.
Researchers at the University of Pittsburgh Cancer Institute (UPCI) and the School of Medicine have discovered that inhibiting a key molecule in a DNA repair pathway could provide the means to make cancer cells more sensitive to radiation therapy while protecting healthy cells.
In this survey, conducted by the Commonwealth Fund and Modern Healthcare, 89 percent of respondents supported moving forward with the measure's implementation. In related news, the National Committee for Quality Assurance plans this month to begin accrediting accountable care organizations. Meanwhile, in local coverage, North Carolina's health exchange grant remains unspent and a rural California county has its own health reform calculus.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.
› Verified 4 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Schizophrenia has long been known to be highly heritable and is present in approximately 1% of the population. Researchers have been following two paths in their pursuit of identifying schizophrenia risk genes.
Scientists have developed a simple, cheap, accurate test to find undetected landmines.
Researchers at the University of Pittsburgh Cancer Institute (UPCI) and the School of Medicine have discovered that inhibiting a key molecule in a DNA repair pathway could provide the means to make cancer cells more sensitive to radiation therapy while protecting healthy cells.
In this survey, conducted by the Commonwealth Fund and Modern Healthcare, 89 percent of respondents supported moving forward with the measure's implementation. In related news, the National Committee for Quality Assurance plans this month to begin accrediting accountable care organizations. Meanwhile, in local coverage, North Carolina's health exchange grant remains unspent and a rural California county has its own health reform calculus.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.
› Verified 4 days ago
The patient survey data of Encompass Health Home Health Of Central Oklahoma is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 92 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 91 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 87 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 89 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 87 | 78 |
News Archive
Schizophrenia has long been known to be highly heritable and is present in approximately 1% of the population. Researchers have been following two paths in their pursuit of identifying schizophrenia risk genes.
Scientists have developed a simple, cheap, accurate test to find undetected landmines.
Researchers at the University of Pittsburgh Cancer Institute (UPCI) and the School of Medicine have discovered that inhibiting a key molecule in a DNA repair pathway could provide the means to make cancer cells more sensitive to radiation therapy while protecting healthy cells.
In this survey, conducted by the Commonwealth Fund and Modern Healthcare, 89 percent of respondents supported moving forward with the measure's implementation. In related news, the National Committee for Quality Assurance plans this month to begin accrediting accountable care organizations. Meanwhile, in local coverage, North Carolina's health exchange grant remains unspent and a rural California county has its own health reform calculus.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.
› Verified 4 days ago
Encompass Health Home Health Of Central Oklahoma Location: 209 Nw 48th Ave, Norman, Oklahoma 73072 Ratings: Phone: (405) 360-0041 | |
Completecare Home Health , Llc Location: 15951 Little Axe Drive, Suite 1816, Norman, Oklahoma 73026 Ratings: Phone: (405) 701-7085 | |
Doctors Park Home Health,inc Location: 517 East Robinson Street, Norman, Oklahoma 73071 Ratings: Phone: (405) 360-6060 | |
Lifespring Home Health Location: 2411 Springer Drive, Norman, Oklahoma 73069 Ratings: Phone: (405) 329-4545 | |
Sooner Health Services, Inc Location: 3705 West Main, Bldg 7, Park A, Norman, Oklahoma 73072 Ratings: Phone: (405) 321-7400 | |
Healthback Home Health Of Norman, Inc Location: 226 West Gray, Suite 214, Norman, Oklahoma 73069 Ratings: Phone: (405) 842-1700 |